ROLE OF GENOTYPIC VARIANTS OF TNF-a RS1800629 GENE POLYMORPHISMS IN THE DEVELOPMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA

Objective. To study the possible association between the allelic and genotypic variants of TNF-a rsl800629gene polymorphism in the development of cervical intraepithelial neoplasia (CIN). Subjects and methods. A total of 91 ethnic Uzbek ethnic women aged 24 to 50 years (a study group) were examined. The controls were DNA samples from 95 apparently healthy ethnic Uzbek women, from the DNA bank of the Department of Molecular Medicine and Cell Technologies, Research Institute of Hematology and Blood Transfusion. Results. A statistically significant difference was found between the patients with CIN and the healthy donors in the frequency of the allelic variants of the examined TNF-a rsl800629gene polymorphism. The marked increase in the frequency of a heterozygous genotype in the patients with CIN versus the controls is evidence in favor of the associativity of the G/A genotype of rsl800629gene polymorphism of TNF-a, the key proinflammatory cytokine of the immune system, at high risk for CIN. The distribution of the genotypes of rsl800629 polymorphism was as follows: In Subgroup 1, the G/A genotype was 2.8-fold more common than that in the control one. The risk for developing the pathology in the presence of this mutant genotype increased more than four-fold. In Subgroup 2, the frequency of the G/A genotype was also 1.8 times higher than that in the controls; however, due to a small number of the groups examined, this difference proved to be statistically insignificant (%2=2.3; P=0.1; OR=2.0; 95% Cl, 8066, 4.895). Conclusion. There was a significant association between the unfavorable G/A genotypic variant of TNF-a rsl800629 gene polymorphism with the development of CIN, particularly this was clear-cut in the subgroup of patients with endometrial hyperplasia. The identification of the functionally unfavorable genetic marker in women with different cervical lesions makes it possible to predict a risk for CIN and to define the further tactics of therapeutic and preventive measures.

rsl800629, intraepithelial neoplasia